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Oxaliplatin has been a crucial component of combination therapies since admission into the clinic causing modest
gains in survival across multiple malignancies. However, oxaliplatin functions in a non-targeted manner, posing a
difficulty in ascertaining precise efficacy mechanisms. While previously thought to only affect DNA repair
mechanisms, Platinum-protein adducts (Pt-Protein) far outnumber Pt-DNA adducts leaving a big part of oxaliplatin
function unknown. Through preliminary network modeling of high throughput data, this article critically reviews
the efficacy of oxaliplatin as well as proposes a better model for enhanced efficacy based on a network approach.
In our study, not only oxaliplatin’s function in interrupting DNA-replication was confirmed, but also its role in
initiating or intensifying tumorigenesis pathways was uncovered. From our data we present a novel picture of
competing signaling networks that collectively provide a plausible explanation of chemotherapeutic resistance,
cancer stem cell survival, as well as invasiveness and metastases. Here we highlight oxaliplatin signaling networks,
their significance and the clinical implications of these interactions that verifies the importance of network
modeling in rational drug design.
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Oxaliplatin, recognized as a DNA intercalating agent, is
a platinum coordinated complex that is used in conjunc-
tion with different chemotherapies for the treatment of
various cancers [1]. In general, oxaliplatin exhibits more
efficacious behavior in vitro than its close platinum
based counterpart, cisplatin. These effects were demon-
strated through IG50 experiments on a standard NCI
drug screen panel (Figure 1). Oxaliplatin exerts its
effects by interfering with DNA replication and tran-
scription machinery through nuclear DNA adduct forma-
tion [2]. These Pt-DNA adducts typically are in the form
of Pt-Guanine-Guanine (Pt-GG) bonding (Figure 2B)
[3]. Ultimately, Pt-DNA complexes at the nucleotide level
will either activate DNA repair mechanisms or apoptotic
pathways. Interestingly, it has been shown that contrary
to its DNA binding capacity, the rate of protein binding
of oxaliplatin may be significantly higher than its* Correspondence: mohammar@karmanos.org
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in any medium, provided the original work is pcovalent binding to DNA (in cisplatin adducts, a similarly
acting compound, 75-85% of covalent binding occurs
with proteins compared with 5-10% in DNA) exhibiting
significant differences when compared to DNA lesions
[4]. For example, in many cancers there is an over ex-
pression of DNA repair proteins such as DNA pol β and
knock down or under expression of this protein results
in increased sensitivity to oxaliplatin induced DNA dam-
age [5]. These findings build a compelling case for the
exploration of protein expression profiles of oxaliplatin
treatment, as the specificity of oxaliplatin is not limited
to Pt-DNA adducts. Thus, a further examination of oxali-
platin and other platinum compounds used in adjuvant
therapies effect on protein expressions is vital to under-
standing efficacy or lack thereof.
Clinically, the use of oxaliplatin is efficacious only
when combined with other agents such as 5-fluorouracil
(5-FU) and leucovorin (LV). Prior to entry into US
clinics, oxaliplatin was used against colorectal cancer
where it did not show, any significant improvement. In
relapsed patients treated with both standard 5-FU and
LV, oxaliplatin addition to the combination elicited a 9%
greater response to treatment than 5-FU/LV infusionOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 A comparison of cisplatin and oxaliplatin IG50 results on a standard NCI drug screen panel. Adapted from Oxaliplatin,
Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute's
Anticancer Drug Screen Panel, Rixe et al. 1996 from the journal Biochemical Pharmacology (OpenAccess, which allows unrestricted use of the
figures).
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with an estimated increase of 2 months in median-
survival time [6]. Today, this combination, known as
FOLFOX, is considered as standard first line treatment
of colorectal cancer and trials in other malignancies,
such as pancreatic cancer, are continuously being
designed. In these combinations, sequence of treatment,
treatment duration and cytotoxicity are very dynamic
and sensitive resulting in different efficacy rates. Unfor-
tunately, most of these studies involving such combina-
tions have not been able to increase overall survival
significantly, further creating a pressing need for new
systemic treatments in complex cancer types [7]. Adjuvant
therapy using oxaliplatin post-resection in colorectalcancer has modestly increased survival but overall outcome
as a single agent in comparison to various treatments
remains unknown [8].
Utilizing these findings and in view of the pressing
need for newer aggressive treatment models, a prelimin-
ary analysis of oxaliplatin treated pancreatic cancer cells
was carried out using gene expression microarrays and
network modeling. The intention was to determine the
primary effects of oxaliplatin on protein interaction net-
works in these cells. Addressing these protein interac-
tions would help characterize where oxaliplatin succeeds
as a single agent or in combination as well as help
understand the underlying mechanisms for its failure. In
doing so, an elementary model can be formulated
Figure 2 Oxaliplatin elucidated action mechanism centers
around the formation of Pt-GG adducts in DNA. (A). This Pt-DNA
NMR structure visualizes the 15 lowest energy solution structures of
Oxaliplatin-GG 12-mer DNA adduct (B). Figures were adapted from
Protein Interactions with Platinum-DNA Adducts: From Structure to
Function, Chaney et al. 2004 from the Journal of Inorganic
Biochemistry (OpenAccess, which allows unrestricted use of the
figures).
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activated in the cell and through this, develop a predict-
ive model for success or failure of an agent based on
already confirmed observations in the knowledge.
Protein interactions and drug efficacy
Benign cellular pathways are complex, malignant ones
more so [9]. One protein’s presence can have a drastic
effect on a multitude of proteins and pathways and the
interrelationships between seemingly unrelated proteins
and pathways is only now coming to light [10]. Interfer-
ing with transcription of a single protein or even halting
it altogether may have a positive result in patient care,
yet over time the disease evolves to activate and upregu-
late other proteins and pathways rendering some cancers
incredibly resistant to chemotherapeutic treatments [11].
What essentially occurs is the network component
which has been altered or inhibited by treatment is com-
pensated for by other members of a broader network.
Thus, an emerging goal in cancer treatment is not just
the targeting of single proteins, but engaging an entireTable 1 Based on expression data, molecules relevant to
oxaliplatin’s mode of action were activated, shown here
Multi-targeted effects of oxaliplatin
Signaling network # Up regulated
Nucleotide Excision Repair 80%
RNA Pol II Complex Assembly 80%
CHK Related Cell Cycle Control 70%
Death Receptor Signaling 70%network and its related networks to halt or reverse the
disease [12]. Moreover, oxaliplatin has been implicated
in Pt-protein adducts, and more and more significance is
being placed upon this interaction as something more
than just drug inactivation [13]. The effects of oxaliplatin
protein adducts remain poorly understood but further
research can yield results shedding light on key interac-
tions relating to efficacy and toxicity.
Oxaliplatin targets protein networks
Initial analyses of high throughput data might suggest at
the outset that a drug works through activation of previ-
ously elucidated pathways [14]. To address this, we car-
ried out microarray expression profiling and network
modeling to understand the oxaliplatin response signa-
tures using a genetically complex pancreatic cancer cell
line model. The design and analysis of data has been
provided in our previous publications [15,16]. In this
study, various mechanisms suggestive of oxaliplatin and
its MDM2 inhibitor combination were investigated using
systems science. However, single agent oxaliplatin pro-
tein network changes were not investigated. Using
Capan-2 (wt-p53) model, we investigated the gene ex-
pression that was followed by Ingenuity network analysis
(IPA) for pathway interactions. Table 1, shows data of
known biochemical interactions of oxaliplatin. Among
the 35 molecules included within the nucleotide excision
repair pathway, nearly 80% were upregulated indicating
DNA damage and its concurrent response. Similarly, in
56 molecules related to the RNA polymerase II complex
assembly mechanism, nearly 80% were upregulated and
nearly 70% of CHK related proteins involved in cell cycle
checkpoint control were upregulated with more than
70% of death receptor signaling components activated as
well. To our surprise we observed activation in compet-
ing carcinogenesis pathways as well. 379 molecules asso-
ciated with broad cancer promoting mechanisms were
found to be upregulated. In Table 2, disease prioritizing
analyses showed up-regulation in 45 molecules asso-
ciated to renal carcinoma, 47 molecules associated to
small cell lung cancer, 39 molecules of non-small cell
lung cancer signaling, 116 molecules implicated in colo-
rectal cancer signaling, 53 molecules in prostate cancer
signaling, 82 molecules of acute myeloid leukemia sig-
naling, 46 molecules in thyroid cancer, 92 molecules of
bladder cancer signaling, 65 molecules of pancreatic
adenocarcinoma signaling, and 64 molecules of ovarian
cancer signaling. Alternate pathways implicated in tumor
growth also exhibited upregulation such as VEGF signal-
ing with 49 molecules.
These results point to a remarkable complexity of
drug action, but it also speaks to the multiple layers of
competition to efficacy that exist. Network theory helps
determine the interrelationships between these various
Table 2 Malignant networks also are partly activated by
oxaliplatin treatment, indicating an inherent competition
between efficacy and toxicity which can be characterized
based on high throughput analysis
Overview of some signaling changes upon oxaliplatin treatment
Signaling network Molecules in
dataset
# Up
regulated
# Down
regulated
Ovarian Cancer 64 34 30
Glioma Signaling 50 26 24
Prostate Cancer 53 31 22
Non-Small Cell Lung Cancer 39 25 14
Colorectal Cancer Metastasis 116 59 57
Basal Cell Carcinoma 25 13 12
Melanoma 25 14 11
Small Cell Lung Cancer 47 28 19
VEGF 49 25 24
Renal Cell Carcinoma 45 30 15
Sonic Hedgehog 15 7 8
Pancreatic Adenocarcinoma 65 37 28
Table 3 Four molecules were selected based on their fold
changes as well as related interacting networks, placing
them in the center of a complicated array of cellular
events affecting disease progression
Major metastasis networks activated by oxaliplatin treatment
Signaling node Fold change
FOS +2.097
NOTCH +1.266
FAF -2.736
VSNL1 -3.343
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achieved simply by understanding the big molecular
picture. Many of these pathways feature molecules
which are related to other pathways mentioned,
whether directly or indirectly. This crosstalk between
components is only now being understood in a clinical
context and has spurred the development of network
pharmacology as a tool to better elucidate drug targets
and better design their drugs. The existence of such
complications explains the vast difficulties encountered
in clinical trials with novel compounds. The nuanced
differences between in vitro and in vivo models for the
development of pharmaceuticals have been long known
and have expressed themselves in unanticipated toxici-
ties uncovered in initial trials. By further validating the
network components of a disease, its relationship to
other networks and a compound’s effect on these net-
works, toxicity can be better predicted based on a con-
sistent system model which may be malleable to each
patient’s own unique molecular disease network. Thus,
precise response can be better predicted long before a
drug enters the clinical trial stage.
Based on the vast body of science available and
results from high throughput data, we are able to
compile a preliminary explanation in a molecular net-
work sense of why oxaliplatin as a single agent simply
does not work (summarized in Table 3). In response
to this, a more in depth analysis of combinations with
oxaliplatin and other family member compounds such
as cisplatin or their combination partners (e.g. FOL-
FOX) is required to better assess true efficacy inpatients. In doing so, better combinations can be
developed using already approved compounds present
in the market.
FOS signaling – Overexpressed with oxaliplatin treatment
FOS signaling was shown activated with treatment of
oxaliplatin in relation to control. The FOS family of pro-
teins consists of four members forming an AP-1 tran-
scription factor complex, FOS, FOSB, FOSL1 and
FOSL2. Early studies indicated marked expression of
FOS in many malignancies including a possible link be-
tween increased c-fos mRNA expression and relapse of
acute childhood lymphoblastic leukemia [17]. Similarly,
in some non small cell lung carcinoma patients surviv-
ability decreased with overexpression of FOS products
[18]. Furthermore, recent studies demonstrate the AP-1
complex being at a significant upstream point, possibly
regulating the expression of critical pathway signaling
components such as the little understood AKR1B10
marker in carcinogenesis [19]. In breast cancer, studies
have implicated FOS as a critical member in the activa-
tion of MMP-9 by S1P, resulting in enhanced invasive-
ness and migration of breast cancer cells [20].
Concurrently, FOS was demonstrated as a possible prog-
nostic marker for clinical decision making with BCL2 in
endocrine breast cancer tumors [21].
NOTCH Signaling – Overexpressed with oxaliplatin
treatment
Faulty NOTCH expression as well as related family
members have been implicated in multiple human dis-
eases since association with T-cell acute lymphoblastic
leukemia in 1991 [22]. Many studies have demonstrated
higher expression of NOTCH in human malignancies
ranging from head and neck cancers, to cervical, lung
and pancreatic cancers and also implicating it in
epithelial-mesenchymal transition (EMT), a major sig-
nal of cancer-stem cells in resistant malignancies [23].
NOTCH signaling has been observed in crosstalk with
NF-κB signaling, resulting in increased transcription of
NOTCH targets and concurrent increase of carcinogen-
esis [24]. A multitude of other crosstalk targets have
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very complicated network. These findings as well as
further elucidation of NOTCH signaling downstream
effects render it an appealing target in cancer treatment
[25]. Figure 3 demonstrates the array of related expres-
sion changes of NOTCH signaling with oxaliplatin
treatments.
FAF1 signaling – Under expressed with oxaliplatin
treatment
FAF1, a component of the Fas death-inducing signaling
complex, was remarkaby under expressed relative to
control. Contemporary observations have shown a
repeated loss or under expression of FAF1 in some can-
cers, possibly indicating anti-tumor activity. Experiments
have demonstrated a physical interaction between FAF1
and β-catenin whereas an increase in FAF1 resulted
in decreased Wnt reporter activity and an increase in
β-catenin cytosolic degradation [26]. Simultaneously,
FAF1 down regulation has been associated with aberrant
NF-κB function.
VSNL1 signaling – Under expressed with oxaliplatin
treatment
A member of the NCS family of proteins, VILIP-1 (a
product of the VSNL-1 gene) is found expressed primar-
ily in the tissues of the CNS as well as other peripheral
tissues in humans and rats [27]. Various experiments
carried out have demonstrated an inverse correlation be-
tween VILIP-1 expression and tumor aggression,Figure 3 Based on expression data from oxaliplatin treated pancreati
elucidated, prioritizing possible targets for treatment.whereby a down regulation is observed in various
human squamous cell carcinomas (SCC) through activa-
tion of cAMP- or cGMP-signaling pathways [28]. In one
elegant study, transfection of mouse SCC lines with
VILIP-1 cDNA resulted in an observable reduction of
invasiveness correlating with elevated cAMP levels and
reduced MMP-9 and RhoA activity [29]. Loss of VILIP-1
expression paralleled clinicopathological features of SCC
in terms of tumor invasiveness as well as local lymph
node metastasis. Further evidence has linked VILIP-1
loss with tumor development in neuroblastoma and
esophageal SCC and analyses have shown a marked
VILIP-1 loss in prostate, lung, ovarian, renal, melanoma
and leukemia cancer cells [30]. Taken together, these
findings suggest an intricate involvement of VILIP-1 in
tumor suppression, of which the precise mechanisms are
still being explored.
Clinical significance and future directions
As drugs are developed and approved, we still lack a co-
herent and consistent method of predicting efficacy and
toxicity in a human model. Based on this preliminary
data, we are able to construct roughly a theoretical pre-
dictive model of toxicity based on network response.
Oxaliplatin serves only as a starting point for determin-
ing the veracity of a network approach to drug interac-
tions. Fundamentally, the cancer network is dynamic
and drug interactions contribute another complex de-
gree of relationships. While the efficacy of oxaliplatin is
not in dispute, the degree of efficacy or efficiency ofc cancer cells, a list of interactions can be surmised and nodes
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liminary review.
The degree to which treatment efficiency is successful
would be highly dependent on advancements in patient
and disease stratification. By characterizing the precise
network regulators of a cancer type, further elucidating
the nuanced differences between subtypes and further
between patients, a targeting motif can be developed.
Utilizing this same information, key predictors of patient
response can be elucidated, further enhancing clinical ef-
ficacy of a drug or guiding combination treatments that
may otherwise not already exist. In using oxaliplatin we
determined the possibility of incidental activation of un-
desired networks, competing with the efficacy if the
drug. By isolating some of these key nodes, a better and
more effective targeting strategy can take place increas-
ing the efficacy of a single agent even with already avail-
able treatments used off-label.
Conclusions
In this study we sought to elucidate the degree of effi-
cacy of oxaliplatin by initially examining high through-
put data of oxaliplatin treated capan-2 pancreatic cancer
cells. While the efficacy of oxaliplatin was not in debate,
the precise cellular mRNA expression profile of single
agent treatment had not been previously explored in
depth. Preliminary results indicated true to form activa-
tion of DNA repair machinery and stress response
mechanisms, in line with the established efficacy of oxa-
liplatin. Surprisingly however, upon treatment several
key genes implicated in tumorigenesis, invasiveness and
migration displayed either over expression against a
desired under expression or vice versa, indicating the ac-
tivation of pathways competing with oxaliplatin efficacy.
Through these preliminary findings, we highlight the im-
portance of oxaliplatin’s effect on FOS, NOTCH, FAF1
and VSNL1 signaling networks representing a sampling
of competing pathways. Using network theory and
already established protocols and scientific knowledge,
efficacy networks can be developed to guide drug devel-
opment as well as the establishment of combination
regimens, increasing the possibility of positive patient re-
sponse and providing more reliable clinical tools for in-
dicating disease state and treatment efficiency. With the
existing technology and knowledge already available,
truly personalized treatment is achievable and within
reach, possibly spelling the end of cancer lethality within
our lifetime.
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